Analysts lose confidence in Biogen Alzheimer's approval

There have been so many controversies surrounding Biogen's drug candidate for Alzheimer's disease, aducanumab, that analysts now see its approval chances as vanishingly low.

Photo: Steven Senne/AP/Ritzau Scanpix

With the deadline for the FDA (US Food and Drug Administration)'s decision on Biogen's drug aducanumab fast approaching, analysts at RBC Capital Markets are less and less convinced that the result will be in Biogen's favor, writes Fiercepharma.

Aducanumab has faced many problems throughout the regulatory process. The application was turned down by an FDA expert committee in November, and the response deadline was pushed back by the agency in January.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs